Dietary low linolenic acid compared with docosahexaenoic acid alter synaptic plasma membrane phospholipid fatty acid composition and sodium-potassium ATPase kinetics in developing rats.
The objective of this study was to investigate if maternal dietary 20:4n-6 arachidonic acid (AA) and 22:6n-3 compared with adequate or low levels of 18:3n-3 linolenic acid (LNA) increases synaptic plasma membrane (SPM) cholesterol and phospholipid content, phospholipid 20:4n-6 and 22:6n-3 content, and Na,K-ATPase kinetics in rat pups at two and five weeks of age. At parturition, Sprague-Dawley rats were fed semi-purified diets containing either AA + docosahexaenoic acid (DHA), adequate LNA (control; 18:2n-6 : 18:3n-3 ratio of 7.1 : 1) or low LNA (18:2n-6 : 18:3n-39 ratio of 835 : 1). During the first two weeks of life, the rat pups received only their dams' milk. After weaning, pups received the same diet as their respective dams to five weeks of age. No significant difference was observed among rat pups fed the diet treatments for SPM cholesterol or total and individual phospholipid content at two and five weeks of age. Fatty acid analysis revealed that maternal dietary AA + DHA, compared with feeding the dams the control diet or the low LNA diet, increased 20:4n-6 in phosphatidylserine and 22:6n-3 content of SPM phospholipids. Rats fed dietary AA + DHA or the control diet exhibited a significantly increased Vmax for SPM Na,K-ATPase. Diet treatment did not alter the Km (affinity) of SPM Na,K-ATPase in rat pups at two and five weeks of age. It is concluded that dietary AA + DHA does not alter SPM cholesterol and phospholipid content but increases the 22:6n-3 content of SPM phospholipids modulating activity of Na,K-ATPase.
Bowen
Raffick A R
RA
Nutrition and Metabolism Research Group, Departments of Agricultural, Food and Nutritional Science and Medicine University of Alberta, Edmonton, Alberta, Canada.
Clandinin
Michael T
MT
D000284:Administration, Oral; D000367:Age Factors; D000818:Animals; D002784:Cholesterol / Q000032:analysis / Q000378:metabolism; D004281:Docosahexaenoic Acids / Q000494:pharmacology*; D004789:Enzyme Activation / Q000502:physiology; D005227:Fatty Acids / Q000032:analysis / Q000378:metabolism*; D005260:Female; D005526:Food, Formulated / Q000032:analysis; D005766:Gastrointestinal Contents / Q000737:chemistry; D006128:Growth; D008297:Male; D010716:Phosphatidylinositols / Q000032:analysis; D010718:Phosphatidylserines / Q000032:analysis; D010743:Phospholipids / Q000737:chemistry / Q000378:metabolism*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012737:Sex Factors; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism*; D013569:Synapses / Q000378:metabolism; D013570:Synaptic Membranes / Q000737:chemistry / Q000378:metabolism*; D017962:alpha-Linolenic Acid / Q000494:pharmacology*
D005227:Fatty Acids; D010716:Phosphatidylinositols; D010718:Phosphatidylserines; D010743:Phospholipids; D017962:alpha-Linolenic Acid; D004281:Docosahexaenoic Acids; D002784:Cholesterol; D000254:Sodium-Potassium-Exchanging ATPase